{
    "clinical_study": {
        "@rank": "24898", 
        "arm_group": [
            {
                "arm_group_label": "Diffuse Large B Cell Lymphoma", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Mantle Cell Lymphoma", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Follicular Lymphoma", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in\n      patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell\n      lymphoma (MCL) or follicular lymphoma (FL)."
        }, 
        "brief_title": "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient has a histologically confirmed diagnosis of mantle cell lymphoma, follicular\n             lymphoma, or diffuse large B cell lymphoma.\n\n          2. Patient has relapsed or refractory disease and received at least one prior therapy.\n\n          3. Patient with diffuse large B cell lymphoma has received or is ineligible for\n             autologous or allogeneic stem cell transplant.\n\n          4. Patient has at least one measurable nodal lesion (\u22652 cm) according to Cheson criteria\n             (Cheson 2007). In case where the patient has no measurable nodal lesions \u2265 2 cm in\n             the long axis at baseline, then the patient must have at least one measurable\n             extra-nodal lesion.\n\n          5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\n\n          6. Patient has adequate bone marrow and organ function.\n\n        Exclusion Criteria:\n\n          1. Patient has received previous treatment with PI3K inhibitors\n\n          2. Patient has evidence of graft versus host disease (GVHD).\n\n          3. Patient has active or history of central nervous system (CNS) disease.\n\n          4. Patient has a concurrent malignancy or has a malignancy within 3 years of study\n             enrollment (with the exception of adequately treated basal or squamous cell carcinoma\n             or non-melanomatous skin cancer).\n\n          5. Patient has a score \u2265 12 on the PHQ-9 questionnaire.\n\n          6. Patient has a GAD-7 mood scale score \u2265 15.\n\n          7. Pregnant or nursing women\n\n          8. Patient who does not use highly effective contraception methods to avoid becoming\n             pregnant or conceiving offspring.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693614", 
            "org_study_id": "CBKM120Z2402", 
            "secondary_id": "2012-002208-41"
        }, 
        "intervention": {
            "arm_group_label": [
                "Diffuse Large B Cell Lymphoma", 
                "Mantle Cell Lymphoma", 
                "Follicular Lymphoma"
            ], 
            "description": "100 mg once a day", 
            "intervention_name": "BKM120", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Diffuse large B-cell lymphoma, Mantle cell lymphoma, Follicular lymphoma, PI3K inhibitor, Non-Hodgkin lymphoma, NHL", 
        "lastchanged_date": "March 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "cconnolly1@partners.org", 
                    "last_name": "Christine Connolly", 
                    "phone": "617-726-4000"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Barnes", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center BKM120Z2402-DFCI"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "mahohens@unmc.edu", 
                    "last_name": "Maribeth Hohenstein", 
                    "phone": "+1 402 559 9053"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68198"
                    }, 
                    "name": "University of Nebraska Medical Center Univ Nebraska"
                }, 
                "investigator": {
                    "last_name": "R. Gregory Bociek", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oneillg@mskcc.org", 
                    "last_name": "Gerald O'Neill", 
                    "phone": "212-639-5059"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Dept of Onc."
                }, 
                "investigator": {
                    "last_name": "Anas Younes", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "snidersh@musc.edu", 
                    "last_name": "Sarah Snider", 
                    "phone": "843-792-1463"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina -Hollings Cancer Center Medical Univ of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Luciano Costa", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sparker@mdanderson.org", 
                    "last_name": "Shapatra Parker", 
                    "phone": "713-792-9455"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(3)"
                }, 
                "investigator": {
                    "last_name": "Jason Westin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Godinne", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Curitiba", 
                        "country": "Brazil", 
                        "state": "PR", 
                        "zip": "81520-060"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90035-903"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barretos", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "14784-400"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Campinas", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "13083-970"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre-Benite C\u00e9dex", 
                        "country": "France", 
                        "zip": "F-69495"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35019"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20141"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20133"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-769"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "state": "Korea", 
                        "zip": "135-710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "738-736"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "state": "Castilla y Leon", 
                        "zip": "37007"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de LLobregat", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08907"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atakum / Samsun", 
                        "country": "Turkey", 
                        "zip": "55139"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35040"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Brazil", 
                "France", 
                "Germany", 
                "Italy", 
                "Korea, Republic of", 
                "Spain", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label Phase II Study of BKM120 in Patients With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Italy: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective Response rate is the number of patients in a cohort who experience either complete response (CR) or partial response (PR) during their follow-up after treatment start divided by the total number of patients included in the corresponding cohort", 
            "measure": "Objective Response rate", 
            "safety_issue": "No", 
            "time_frame": "Treatment continues in cycles of 28 days until disease progression, intolerable toxicity, other criteria for discontinuation, or 6 months after the last patient in that cohort has started BKM120, whichever comes first."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693614"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival (PFS) is the time from the date of treatment start to the date of the first documented progressive disease (PD) or death due to any cause", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Every 2 cycles until disease progression, new anticancer therapy, lost to follow up, death, consent withdrawal or 6 months after the last patient in that cohort has started the study treatment, whichever comes first."
            }, 
            {
                "description": "Duration of response is the time from the date of first occurrence of complete response (CR) or partial response (PR) to the date of the first documented progressive disease (PD) or death due to any cause", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Every 2 cycles until disease progression,new anticancer therapy, lost to follow up, death, consent withdrawal or 6 months after the last patient in that cohort has started treatment, whichever comes first."
            }, 
            {
                "description": "Overall survival (OS) is the time from treatment start to the date of death due to any cause", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Every 2 cycles until disease progression, new anticancer therapy, lost to follow up, death, consent withdrawal, or 6 months after the last patient in that cohort has started treatment, whichever comes first."
            }, 
            {
                "description": "Safety will be determined by type, frequency and severity of adverse events per CTCAEv4.03 and type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Continuous, until 30 days after treatment stops"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}